BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17384675)

  • 21. Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand.
    Yoshida T; Maoka T; Das SK; Kanazawa K; Horinaka M; Wakada M; Satomi Y; Nishino H; Sakai T
    Mol Cancer Res; 2007 Jun; 5(6):615-25. PubMed ID: 17579120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
    Iacomino G; Medici MC; Russo GL
    Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
    Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
    Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
    Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
    Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole.
    Goda AE; Yoshida T; Horinaka M; Yasuda T; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2008 May; 27(24):3435-45. PubMed ID: 18193086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage.
    Jin CY; Park C; Moon SK; Kim GY; Kwon TK; Lee SJ; Kim WJ; Choi YH
    Anticancer Drugs; 2009 Sep; 20(8):713-22. PubMed ID: 19617819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
    Siegelin MD; Gaiser T; Habel A; Siegelin Y
    Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Mitterberger M; Neuwirt H; Cavarretta IT; Hobisch A; Culig Z
    Prostate; 2007 Aug; 67(11):1194-201. PubMed ID: 17520660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2.
    Siegelin MD; Gaiser T; Habel A; Siegelin Y
    Neurosci Lett; 2009 May; 454(3):223-8. PubMed ID: 19429088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
    Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
    J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis.
    Siegelin MD; Habel A; Gaiser T
    Neurobiol Dis; 2009 Feb; 33(2):243-9. PubMed ID: 19027068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling.
    Jeon YJ; Kim IK; Hong SH; Nan H; Kim HJ; Lee HJ; Masuda ES; Meyuhas O; Oh BH; Jung YK
    Oncogene; 2008 Jul; 27(31):4344-52. PubMed ID: 18362888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells.
    Chen W; Wang X; Zhuang J; Zhang L; Lin Y
    Carcinogenesis; 2007 Oct; 28(10):2114-21. PubMed ID: 17548900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.